Menu

Locally-Injected Immunotherapy Eradicates Tumors in Mice

The treatment also curbed the growth of nearby metastases that did not receive the drug.

Feb 1, 2018
Diana Kwon

ISTOCK, VKOVALCIK

Using a process called in situ vaccination, in which the host’s immune system is recruited to attack cancer cells, researchers were able to clear injected tumors—and nearby metastases—in mice, according to a study published yesterday (January 31) in Science Translational Medicine.

Scientists at Stanford University injected a pair of molecules—an antibody against a protein on the surface of T cells, known as OX40, and a short piece of DNA called a CpG oligodeoxynucleotide—into various types of solid tumors, including melanoma and breast and colon cancers, in mice. “When we use these two agents together, we see the elimination of tumors all over the body,” Ronald Levy, an oncologist at Stanford University, says in a statement. “This approach bypasses the need to identify tumor-specific immune targets and doesn't require wholesale activation of the immune system or customization of a patient's immune cells.”

Levy and his team also tested the approach on a mouse strain prone to a highly invasive form of breast cancer that often metastasizes, and found that the treatment reduced the size of the injected tumor and nearby cancerous growths. It was also able to prevent further tumor development.

“The data is very impressive, particularly for the uninjected tumors,” Drew Pardoll, a cancer immunologist at the Bloomberg~Kimmel Institute for Cancer Immunotherapy who did not take part in the study, tells Science.

“This early research in mice suggests that this could be an effective way of engaging the immune system to tackle cancer,” Catherine Pickworth of Cancer Research UK tells The Telegraph“These types of treatments are exciting but can be complicated—one of the biggest challenges of immunotherapies is predicting how they will work with patients’ immune systems, and understanding what the side effects could be.”

Levy and colleagues are now launching a clinical trial to test the injection in patients with lymphoma.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
Cell culture made easy with new 24-channel pipetting heads for VIAFLO 96/384
INTEGRA has responded to customers’ requests and developed two new 24-channel pipetting heads, extending the capabilities of its popular VIAFLO 96/384.
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.